Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melissa Clayton

Nurse Practitioner, Adult Health Chester, VA Nurse Practitioner

NPI 1548298847 CMS profile 11221157

11601 Iron Bridge Rd, Suite 117, Chester, VA 23831

Open in the dashboard

General payments

$3,145

184 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melissa Clayton of Chester, VA is reported in the CMS Open Payments database as having received $3,145 across 184 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $294 6
2024 General $73 4
2023 General $1,084 69
2022 General $825 51
2021 General $869 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Clayton
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Melissa Clayton were reported at $294. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Melissa Clayton Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $869 $138 $43–$438 $132
2022 $825 $165 $54–$494 $149
2023 $1,084 $178 $61–$549 $160
2024 $73 $186 $62–$575 $164
2025 $294 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $774 61 payments
  2. Novo Nordisk Inc $282 18 payments
  3. Esperion Therapeutics, Inc. $249 10 payments
  4. Pfizer Inc. $238 9 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $136 6 payments
  6. Biohaven Pharmaceuticals, Inc. $126 9 payments
  7. Abbott Laboratories $105 6 payments
  8. Eisai Inc. $104 1 payment
  9. Exact Sciences Corporation $97 5 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $94 4 payments
  11. Other $940 55 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,138 183 payments
  2. Education $7 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $279 22 payments
  2. UBRELVY $271 22 payments
  3. NURTEC ODT Primary Care $262 15 payments
  4. NEXLETOL $249 10 payments
  5. Ozempic $237 15 payments
  6. RYBELSUS $237 15 payments
  7. QULIPTA $233 18 payments
  8. NURTEC ODT Pain $231 8 payments
  9. NEXLIZET $125 1 payment
  10. PAXLOVID $114 7 payments
  11. Other $2,009 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 193 drugs

Part D claims

13,645

Median for Nurse Practitioner: 389

Drug cost

$918,778

Median for Nurse Practitioner: $21,885

Branded share of claims

21.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 90 $138,437
Januvia Sitagliptin Phosphate Brand 79 $80,729
Trulicity Dulaglutide Brand 46 $69,602
Eliquis Apixaban Brand 61 $66,798
Jardiance Empagliflozin Brand 57 $54,656
Xarelto Rivaroxaban Brand 53 $43,299
Linzess Linaclotide Brand 49 $33,869
Tradjenta Linagliptin Brand 29 $31,316
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $30,735
Farxiga Dapagliflozin Propanediol Brand 31 $26,262

The 10 drugs with the highest cost, of 193 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$29,438

Medicare's payments for the services billed

Medicare patients

345

Average age 72

Services billed

882

258 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 36%
Arthritis 35%
Chronic kidney disease 26%
Ischemic heart disease 21%
Depression 21%
Heart failure 16%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record